Skip to main content

Table 4 Binary logistic regression analysis for the associations between parameters of glycemic variability and the presence of CAN

From: The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes

Long-term GV OR (95 % CI) p value Short-term GV OR (95 % CI) p value
SD of HbA1c    SD of glucose   
  Crude 14.33 (3.45–59.48) <0.001   Crude 1.04 (1.01–1.07) 0.002
  Model 1 16.09 (3.55–73.00) <0.001   Model 1 1.04 (1.01–1.07) 0.010
  Model 2 9.31 (1.91–45.42) 0.028   Model 2 1.02 (0.99–1.05) 0.205
  Model 3 12.10 (2.29–63.94) 0.003   Model 3 1.02 (0.99–1.05) 0.216
Adjusted SD of HbA1c   MAGE   
  Crude 21.22 (4.24–106.30) <0.001   Crude 1.01 (0.99–1.02) 0.064
  Model 1 23.54 (4.28–129.69) <0.001   Model 1 1.01 (0.99–1.02) 0.145
  Model 2 13.39 (2.25–79.82) 0.004   Model 2 1.00 (0.99–1.02) 0.676
  Model 3 17.02 (2.66–108.86) 0.003   Model 3 1.00 (0.99–1.02) 0.781
Log CV of HbA1c   CV of glucose   
  Crude 19.90 (3.47–113.69) 0.001   Crude 1.07 (1.02–1.12) 0.009
  Model 1 23.88 (3.77–151.52) 0.001   Model 1 1.07 (1.01–1.13) 0.014
  Model 2 16.72 (2.43–115.04) 0.004   Model 2 1.06 (1.01–1.13) 0.028
  Model 3 24.00 (3.09–186.48) 0.002   Model 3 1.07 (1.01–1.13) 0.033
  1. Model 1 was adjusted for age, sex and duration of diabetes. Model 2 was additionally adjusted for mean HbA1c over 2 years. Model 3 was additionally adjusted for medication (insulin, oral anti-diabetic drug, aspirin, beta-blocker, ARB/ACE inhibitor) and smoking status
  2. CAN cardiovascular autonomic neuropathy, SD standard deviation, MAGE mean amplitude of glycemic excursions, CV coefficient of variance